

29 November 2019

## Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> December 2019 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Olopatadine	Eye drops 0.1% (5 ml bottle OP)	\$10.00	\$2.20	Olopatadine Teva (Teva)	1 May 2020	1 October 2020	Patanol (Novartis)

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Olopatadine	Eye drops 0.1% (5 ml bottle)	\$10.00	\$2.20	Olopatadine Teva (Teva)	1%	1 May 2020	1 October 2020	Patanol (Novartis)

## Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2017/18 Invitation to Tender, dated 2 November 2017
- the 2018/19 Invitation to Tender, dated 1 November 2018

### *2017/18 Invitation to Tender*

Chemical name	Line item
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
Zoledronic acid	Inj 4 mg per 100 ml

### *2018/19 Invitation to Tender*

Chemical name	Line item
Hydrocortisone	Inj 50 mg per ml, 2 ml

For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.